2013-05-01T10:51:16-05:00 2012-06-30 ERNST & YOUNG US LLP 4370 LA JOLLA VILLAGE DR STE 500 SAN DIEGO CA 92122 990 2011-07-01 952160097 The Salk Institute for Biological Studies % KIM E WITMER SALK 8584534100 10010 N TORREY PINES ROAD La Jolla CA 920371002 KIM E WITMER 2013-05-01 true 8585357200 2011 2016-02-25 16:41:14Z X WILLIAM BRODY 10010 N TORREY PINES ROAD LA JOLLA CA 920371002 172696302 false X WWW.SALK.EDU X 1960 CA BASIC RESEARCH IN THE FOLLOWING: MOLECULAR BIOLOGY & GENETICS, NEUROSCIENCE, AND PLANT BIOLOGY. 29 25 1039 100 -1127 -11376 120830531 141948095 0 0 4885274 4142804 2055609 3114622 127771414 149205521 0 0 0 0 64525936 67662745 0 0 4297991 46459416 52389275 110985352 120052020 16786062 29153501 344678120 357920584 109026302 101386107 235651818 256534477 INVOLVED IN RESEARCH ACTIVITIES, THE OBJECTIVES OF WHICH ARE THE ADVANCEMENT AND DISSEMINATION OF KNOWLEDGE RELEVANT TO THE HEALTH AND WELLBEING OF MAN. THE OBJECTIVES ARE MET PRIMARILY THROUGH RESEARCH AND ADVANCED INSTRUCTION IN (A) BIOLOGY, (B) THE CAUSE, PREVENTION AND CURE OF DISEASES, AND (C) THE FACTORS AND CIRCUMSTANCES CONDUCIVE TO THE FULFILLMENT OF MAN'S BIOLOGICAL POTENTIAL. false false 103461164 LIST OF ACCOMPLISHMENTS 1. "Unnatural" chemical allows Salk researchers to watch protein action in brain cells: Salk scientists have been able to genetically incorporate "unnatural" amino acids, such as those emitting green fluorescence, into neural stem cells, which then differentiate into brain neurons with the incandescent "tag" intact. This new technique, reported in Stem Cells, may help scientists probe the mysteries of many different kinds of stem cells in humans as well as the cells they produce. This could be a boon to both basic and clinical research, such as helping to speed development of stem cell-based regenerative medicine. 2. Salk researchers near goal of using a patient's own cells to make stem cells: A team of Salk researchers developed an improved technique for generating large numbers of blood cells from a patient's own cells. The new technique, published in the journal Stem Cells, will be immediately useful in further stem cell studies and when perfected, could be used in stem cell therapies for a wide variety of conditions, including cancers and immune ailments. 3. A giant leap for plant biology: Salk investigators in collaboration with an international team of scientists recently reported a major leap forward in plant biology, describing in the journal Science their mapping and early analyses of thousands of protein-to-protein interactions within the cells of the model plant Arabidopsis thaliana. With this one study they managed to double the plant protein interaction data that are available to scientists. These data, along with data from future mapping studies, should enable biologists to make agricultural plants more resistant to drought and diseases, more nutritious and generally more useful to mankind. 4. Discovery of insulin switches in pancreas could lead to new diabetes drugs: Salk researchers have discovered how a hormone turns on a series of molecular switches inside the pancreas that increases production of insulin. Published in the Proceedings of the National Academy of Sciences, the finding raises the possibility that new designer drugs might be able to turn on key molecules in this pathway to help the 80 million Americans who have type 2 diabetes or pre-diabetic insulin resistance. The molecular switches command pancreatic beta islet cells, the cells responsible for insulin, to grow and multiply and tweaking these cells might offer a solution to type 1 diabetes, the form of diabetes caused by destruction of islet cells, and to type 2 diabetes, the form caused by insulin resistance. By understanding how pancreatic cells can be encouraged to produce insulin in the most efficient way possible, those cells may be able to be manipulated to treat or even prevent diabetes. Such new agents might increase the functioning of beta islet cells even in people who have not developed diabetes. 5. The genome guardian's dimmer switch: regulating p53 is a matter of life or death: A team of Salk scientists has shed light on the functioning of an important damage response protein in cells. Although the protein, p53, is known as an important tumor suppressor, it is also critical for determining whether a cell survives stress and continues to function in a variety of situations. The study, which appeared in Genes & Development, shows that a short segment on p53 acts as a dimmer switch that helps control the level of p53 activity in a critical stem cell population and the offspring they generate. One implication of the research is that drugs to lower p53 levels, or to reduce its transcription of other growth-stopping genes, might be used temporarily to reduce unwanted tissue damage from DNA-altering drugs or radiation. Another implication is that p53-boosting drugs, which are currently being tested in cancer patients, could have dangerous side effects if used in combination with other drugs that cause DNA damage. 6. Bionic bacteria may help fight disease and global warming: A strain of genetically enhanced bacteria developed by researchers at the Salk Institute may pave the way for new synthetic drugs and new ways of manufacturing medicines and biofuels, according to a paper published in Nature Chemical Biology. For the first time, the scientists were able to create bacteria capable of effectively incorporating "unnatural" amino acids - artificial additions to the 20 naturally occurring amino acids used as biological building blocks - into proteins at multiple sites. This ability may provide a powerful new tool for the study of biological processes and for engineering bacteria that produce new types of synthetic chemicals. 7. Salk breathes new life into fight against primary killer of premature infants: A discovery by scientists at the Salk Institute might explain why some premature infants fail to respond to existing treatments for a deadly respiratory distress syndrome (RDS) and offers clues for new ways to treat the breathing disorder. RDS affects about one percent of infants born in the United States and is the leading cause of death among premature babies. The findings, published in Nature Medicine, identified a new form of RDS in newborn mice and traced the problem to a cellular receptor for thyroid hormone, a key player in many developmental processes in the body. The research has provided new insight toward explaining and treating RDS and other respiratory problems that occur in infants. 8.Long-lived fruit flies offer Salk scientists clues to slowing human aging and fighting disease: A new study in fruit flies, published online in Cell Metabolism, is helping to explain why minimal diets are linked to longevity and offering clues to the effects of aging on stem cell behavior. Scientists at the Salk Institute and their collaborators found that tweaking a gene known as PGC-1, which is also found in human DNA, in the intestinal stem cells of fruit flies delayed the aging of their intestine and extended their lifespan by as much as 50 percent. The findings suggest that the fruit fly version of PCG-1 can act as a biological dial for slowing the aging process and might serve as a target for drugs or other therapies to put the brakes on aging and age-related diseases. 9. Scientists identify gene crucial to normal development of lungs and brain: Researchers at the Salk Institute have identified a gene that tells cells to develop multiple cilia, tiny hair-like structures that move fluids through the lungs and brain. The findings of the research, published in Nature Cell Biology, may help scientists generate new therapies that use stem cells to replace damaged tissues in the lung and other organs. 10. Discovery of plant proteins may boost agricultural yields and biofuel production: In a collaborative study, scientists at the Salk Institute discovered a family of plant proteins that play a role in the production of seed oils, substances important for animal and human nutrition, bio renewable chemicals and biofuels. Scoring a rare scientific hat trick, the researchers identified three related proteins in Arabidopsis thaliana that regulate the metabolism of fatty acids, chemical components of all cell membranes and vegetable oils. They dubbed these fatty-acid binding proteins FAP1, FAP2 and FAP3. The findings, reported in Nature, may lead to the development of improved crops yielding higher qualities and quantities of oils, helping to address growing demands for food and fuel and the consequent environmental pressures on the world's ecosystems. 11. Salk scientists discover chemotherapy pathway: A recent study by Salk investigators showed exactly how cells sense the possibility that their DNA is damaged as a first step to responding to the failure to divide properly. The study, published in Nature Structural and Molecular Biology, found that if cells take too long to undergo cell division, protective structures at the tips of their chromosomes, known as telomeres, send out a molecular SOS. The findings have dual implications for cancer chemotherapy. First, they show how a class of anti-cancer drugs that slows cell division-known as mitotic inhibitors-kills cells. More significantly, the findings suggest ways to make therapy with those inhibitors more potent. 12. Salk study could offer drug-free intervention to prevent obesity and diabetes Salk scientists have found that regular eating times and extending the daily fasting period may override the adverse health effects of a high-fat diet and prevent obesity, diabetes and liver disease in mice. The study, published in Cell Metabolism, reported that mice limited to eating during an 8-hour period are healthier than mice that eat freely throughout the day, regardless of the quality and content of their diet. The study sought to determine whether obesity and metabolic diseases result from a high-fat diet or from disruption of metabolic cycles. Obesity is a major health challenge, reaching global pandemic proportions. Obesity increases the risk of a number of health conditions inc 103461164 true true false true false false false false false true true true false false true false true false false false true false false false true false false false false true true false false false false false true false false false false true false false false false true true false false false true X 143 0 true 1039 true true true false false false false true true false false false false X 29 25 false false false false true true true true true false false true true true true true true true true false AL AK AZ AR CA CT GA HI IL KS KY ME MD MA MI MN MS NH NJ NM NY NC OH OK OR PA RI SC TN UT VA WA WV WI X KIM E WITMER 8584534100 10010 N TORREY PINES ROAD LA JOLLA CA 920371002 X William R Brody MD PhD 50.0 X X 802842 0 143981 Irwin M Jacobs SM ScD 3.0 X X 0 0 0 Darlene M Shiley 2.0 X X 0 0 0 Theodore Waitt 2.0 X X 0 0 0 Thomas D Albright PhD 50.0 X 233830 0 46760 Charles H Brandes 2.0 X 0 0 0 Linda L Chester 0.5 X 0 0 0 Frederick J Dotzler 0.5 X 0 0 0 Jennifer L Howse PhD 0.5 X 0 0 0 Dean Kamen 0.5 X 0 0 0 Christoper R Kintner PHD 50.0 X 203114 0 31266 Benjamin H Lewis 0.5 X 0 0 0 Corinne Mentzelopoulos 0.5 X 0 0 0 Howard H Newman PhD 2.0 X 0 0 0 Ralph S O'Connor 0.5 X 0 0 0 Gerald S Parsky 0.5 X 0 0 0 Frederik Paulsen PhD 0.5 X 0 0 0 Caryl Philips 0.5 X 0 0 0 Conrad T Prebys 0.5 X 0 0 0 Ernest S Rady 0.5 X 0 0 0 Faye H Russell 0.5 X 0 0 0 Mary Jane Salk 0.5 X 0 0 0 Benjamin S Schapiro 0.5 X 0 0 0 Carla J Shatz PhD 0.5 X 0 0 0 Jerre L Stead 2.0 X 0 0 0 Geoffrey M Wahl PhD 50.0 X 247411 0 47227 Harvey P White 0.5 X 0 0 0 Marna C Whittington PhD 0.5 X 0 0 0 M Faye Wilson 0.5 X 0 0 0 Marsha A Chandler PhD 50.0 X 466184 0 33320 Julia A Miller JD 50.0 X 249696 0 15664 Kim E Witmer 50.0 X 353372 0 47514 Fred H Gage PhD 50.0 X 312204 0 43981 Rebecca R Newman 50.0 X 331730 0 40226 Dennis D O'Leary PhD 50.0 X 306350 0 47514 Wylie W Vale PHD 50.0 X 332335 0 43981 Inder Verma PhD 50.0 X 360446 0 43981 4199514 0 585415 80 false true false RUDOLPH SLETTEN INC 10955 VISTA SORRENTO PKWY SAN DIEGO CA 92130 General Contractor 18833015 UC REGENTS SAN DIEGO 9500 GILMAN DRIVE LA JOLLA CA 92093 TRNG PROGRAM/SUBCONT 1668963 SAN DIEGO GAS ELECTRIC PO BOX 129831 SAN DIEGO CA 92112 FACILITIES & MAINT. 1070123 STELLAR SOLAR 6965 EL CAMINO REAL SUITE 105 CARLSBAD CA 92009 SOLAR ENERGY SYSTEM 1847559 SECURITAS SECURITY SERVICE FILE 57220 LOS ANGELES CA 90074 SECURITY 506230 19 580857 65788133 75579105 3558046 141948095 0 1621359 1621359 0 0 2785633 2785633 25746293 44750 23231106 38492 2515187 6258 2521445 2521445 143925 580857 221183 -77258 -77258 0 0 ENERGY REBATE 900099 400580 400580 OIL ROYALTIES 900099 6794 6794 UBI(K-1 FLOW THROUGH INCOME) 900099 -4163 -4163 3036 3036 406247 149205521 -1127 7258553 0 0 0 0 2984331 828212 1963685 192434 699316 699316 48036614 41916570 4082290 2037754 4393488 3635961 562271 195256 8027132 6643090 1027299 356743 3521864 2914623 450722 156519 653287 101824 440283 111180 828021 784472 43549 213982 213982 0 0 204663 204663 5512253 4941999 439097 131157 25467 1603 1556 22308 13872190 13361084 216761 294345 2868830 2441070 342297 85463 0 6134020 4751611 1236316 146093 912030 741628 39984 130418 0 1254875 868431 94877 291567 621 621 0 10615786 9988543 484485 142758 148480 148480 SCIENTIFIC SUBCONTRACTS 7291284 7291284 REPAIRS & PARTS 1460814 1432413 23508 4893 UBI TAXES 2093 2093 OTHER EXPENSES 390579 117430 274046 -897 120052020 103461164 12292865 4297991 10968328 12698201 0 0 24066906 28220160 1367629 922755 148500 148500 0 0 1651234 1608475 125109 86205 783427 678625 213870646 126065190 84139853 87805456 116113310 118874737 91784543 100033993 0 0 0 0 13677781 6843477 344678120 357920584 19343762 17196676 0 0 25466282 21168387 57607080 56129568 0 0 0 0 0 0 0 0 6609178 6891476 109026302 101386107 X 80926968 78170627 58620417 63947145 96104433 114416705 235651818 256534477 344678120 357920584 X 29153501 -8270842 X false true true X true true X 102548502 87583830 114311374 120830531 141948096 567222333 102548502 87583830 114311374 120830531 141948096 567222333 14008590 553213743 1297051 2714020 3494564 3483205 4407819 15396659 105259 44457 149716 22714 3678 222177 18981 407374 674924 583443632 0.94819 0.96050 X DESCRIPTION: GLASS ART TOUR 2007: 0 2008: 0 2009: 210,825 2010: 0 2011: 0 DESCRIPTION: OIL ROYALTIES 2007: 22,714 2008: 3,678 2009: 7,692 2010: 16,701 2011: 6,794 DESCRIPTION: NOTE RECEIVABLE INTEREST 2007: 0 2008: 0 2009: 3,660 2010: 2,280 2011: 0 DESCRIPTION: ENERGY REBATE 2007: 0 2008: 0 2009: 0 2010: 0 2011: 400,580 RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED false false false false false false false false true 2930 2930 false OTHER ACTIVITIES PART II-B, LINE 1i PAID MEMBERSHIP DUES TO RESEARCH AND BIOMEDICAL ORGANIZATIONS, A PORTION OF WHICH ARE CONSIDERED LOBBYING. ASSOCIATION OF INDEPENDENT RESEARCH INSTITUTES $ 720 CALIFORNIA HEALTHCARE INSTITUTE $1,250 NATIONAL ASSOCIATION FOR BIOMEDICAL RESEARCH $ 960 113493623 18776974 -1376528 4168510 126725559 89420545 12288420 15274598 3489940 113493623 71360759 11356891 8833640 2130745 89420545 83049682 2721386 -12462264 1948045 71360759 0.00710 0.99290 false false 1153930 1153930 68485570 37427293 31058277 70556093 38884018 31672075 70199675 49753879 20445796 3475378 3475378 87805456 ALTERNATIVE INVESTMENTS 100030879 F STOCKS NOT-PUBLICLY TRADED <5% 3114 C 100033993 2052 DEFERRED RETIREMENT OBLIGATION 6889424 6891476 149205521 120052020 29153501 -8223913 11554613 3330700 32484201 152756405 -8223913 11553614 3329701 149426704 -221183 -221183 149205521 120273202 221183 221183 120052019 1 1 120052020 CHANGE IN NET ASSETS Part XI, Line 8 Other Investment gains in excess of amount designated for current operations under spending policy plus rounding. RECONCILIATION OF REVENUE PER AUDITED FS WITH REVENUE PER RETURN Part XII, Lines 2d Investment return in excess of amount designated for current operations under spending policy plus rounding. Reconciliation of Revenue per Audited FS with Revenue per Return Part XII, Line 4b Fundraising events expenses. ENDOWMENT FUNDS USES PART V, LINE 4 ENDOWMENT INCOME INTENDED TO BE USED FOR AND TO SUPPORT RESEARCH, OPERATIONS, AND LECTURESHIP EXPENSES. Reconciliation of Expenses per Audited FS with Expenses per Return Part XIII, Line 2d Fundraising events expenses. Reconciliation of Expenses per Audited Financial Stmts w Expenses per Rtn Part XIII, Line 4b Rounding. Europe (Including Iceland and Greenland) Program Services Attended conference 140475 East Asia and the Pacific Program Services Attended conference 53892 Central America and the Caribbean Program Services Attended conference 8510 Middle East and North Africa Program Services Attended conference 6061 North America Program Services Attended conference 20661 South Asia Program Services Attended conference 1889 South America Program Services Attended conference 862 North America Program Services Scientific subcontract 138631 Europe (Including Iceland and Greenland) Program Services Scientific subcontract 74435 South America Program Services Scientific subcontract 48339 East Asia and the Pacific Program Services Scientifc subcontract 9700 Central America and the Caribbean Investments 72857682 73361137 73361137 true false false true false false NO. OF EMPLOYEES IN THE REGION PART I, LINE 3, COLUMN (C) SCIENTISTS TRAVEL TO FOREIGN COUNTRIES TO ATTEND CONFERENCES. WE DO NOT DEEM THESE ACTIVITIES TO CONSTITUTE WORKING IN THE REGION. ACCOUNTING METHOD PART I, LINE 3, COLUMN (F) ACCRUAL METHOD CONCERT 690282 555957 134325 84600 125000 GOLF TOURNAMENT 34500 24900 9600 11583 0 0 0 0 0 0 724782 580857 143925 96183 125000 221183 -77258 X X true true X X X X X X false true false false false false false true false William R Brody MD PhD 642174 0 0 0 160668 0 131850 0 12131 0 946823 0 0 0 Thomas D Albright PhD 231616 0 0 0 2214 0 31096 0 15664 0 280590 0 0 0 Christoper R Kintner PHD 185376 0 0 0 17738 0 26000 0 5266 0 234380 0 0 0 Geoffrey M Wahl PhD 243831 0 0 0 3580 0 31850 0 15377 0 294638 0 0 0 Marsha A Chandler PhD 414116 0 0 0 52068 0 31850 0 1470 0 499504 0 0 0 Julia A Miller JD 248850 0 0 0 846 0 0 0 15664 0 265360 0 0 0 Kim E Witmer 321593 0 0 0 31779 0 31850 0 15664 0 400886 0 0 0 Fred H Gage PhD 307674 0 0 0 4530 0 31850 0 12131 0 356185 0 0 0 Rebecca R Newman 294824 0 0 0 36906 0 31850 0 8376 0 371956 0 0 0 Dennis D O'Leary PhD 264316 0 0 0 42034 0 31850 0 15664 0 353864 0 0 0 Wylie W Vale PHD 316957 0 0 0 15378 0 31850 0 12131 0 376316 0 0 0 Inder Verma PhD 332674 0 0 0 27772 0 31850 0 12131 0 404427 0 0 0 QUESTIONS REGARDING COMPENSATION PART I, LINE 1A FIRST-CLASS OR CHARTER TRAVEL: DENNIS O'LEARY, PROFESSOR - $1,238; NOT TAXABLE - ACCOUNTABLE PLAN. QUESTIONS REGARDING HOUSING ALLOWANCE OR RESIDENCE PART I, LINE 1A A HOUSING ALLOWANCE IS PROVIDED AND REPORTED AS TAXABLE COMPENSATION. SUPPLEMENTAL NONQUALIFIED RETIREMENT PLAN PART I, LINE 4B DEFERRED COMPENSATION PLAN (SECTION 457(F)) WAS ESTABLISHED FOR THE PRESIDENT. THE INSTITUTE'S CONTRIBUTION TO THE PLAN AND THE EARNINGS FROM THE CONTRIBUTION WILL BECOME 100% VESTED UPON THE PRESIDENT'S COMPLETION OF 5 YEARS OF SERVICE. NO PAYOUTS FROM THE PLAN WERE MADE DURING THE YEAR. NON-FIXED PAYMENTS PART I, LINE 7 WYLIE VALE - $3,500 FOR LICENSING CONSULTING. NON-FIXED PAYMENTS INCLUDE BOARD OF TRUSTEE AWARDS WHICH ARE REPORTED UNDER OTHER REPORTABLE COMPENSATION. THE BOARD OF TRUSTEE AWARDS ARE NON-BASE RECOGNITION AWARDS FOR CERTAIN LISTED INDIVIDUAL, AS APPROVED BY THE EXECUTIVE COMMITTEE OF THE BOARD OF TRUSTEES. NON-BASE RECOGNITION AWARDS ARE INCLUDED IN THE TOTAL COMPENSATION PACKAGES SUBJECT TO THE REVIEW PROCESS DESCRIBED IN SCHEDULE O FOR FORM 990, PART VI, SECTION B, LINE 15B. CA STATEWIDE COMM DEV AUTHORITY 680164610 130911S92 2005-08-11 25712839 REFUND 03/30/94 ISSUE false false false COUNTY OF SAN DIEGO 956000934 797391R50 2010-05-27 37207949 REFUND 04/13/00 ISSUE;RENOVATE/EQU false false false 6250000 0 25712839 0 0 0 686939 0 0 0 0 0 true false true true 360000 0 37207949 0 0 0 523682 0 0 23537429 0 0 2012 true false true true 0.00000 0.00000 0.00000 false true false false 0.00000 0.00000 0.00000 true false false false 0 false 0 false true false false false 0 false 0 false true X DENNIS O'LEARY HOME LOAN X 165000 148500 false true true 148500 X 19 3558046 MARKET VALUE false true false GOVERNING BODY AND MANAGEMENT FORM 990, PART VI, SECTION A, LINES 1a, 6, 7a, 7b LINE 1A: THE EXECUTIVE COMMITTEE SHALL ADVISE AND AID THE OFFICERS OF THE CORPORATION IN ALL MATTERS CONCERNING ITS INTERESTS, INCLUDING WITHOUT LIMITATION ALL MATTERS RELATING TO COMPENSATION AND BENEFITS, AND SHALL POSSESS AND MAY EXERCISE, DURING THE INTERVALS BETWEEN THE MEETINGS OF THE BOARD OF TRUSTEES, ALL THE POWERS AND AUTHORITY OF THE BOARD OF TRUSTEES IN THE MANAGEMENT OF THE BUSINESS AND AFFAIRS OF THE CORPORATION, INCLUDING THE POWER TO AUTHORIZE THE CORPORATE SEAL TO BE AFFIXED TO ANY AND ALL DOCUMENTS WHICH MAY REQUIRE THE SAME TO BE AFFIXED THERETO, INSOFAR AS SUCH SEEMS TO THE EXECUTIVE COMMITTEE FOR THE BEST INTERESTS OF THE CORPORATION, IN ALL CASES IN WHICH SPECIFIC DIRECTIONS SHALL NOT HAVE BEEN GIVEN BY THE BOARD OF TRUSTEES, EXCEPT THAT THE EXECUTIVE COMMITTE SHALL HAVE NO POWER TO ADOPT, AMEND, OR REPEAL THE BY-LAWS. LINE 6: MEMBERSHIP OF THE CORPORATION CONSISTS OF THE PERSONS ELECTED TO THE BOARD OF TRUSTEES AND THREE MEMBERS FROM AMONG THE RESIDENT AND NON-RESIDENT FELLOWS AND PROFESSORS CHOSEN AND ELECTED ANNUALLY BY THE RESIDENT AND NON-RESIDENT FELLOWS AND PROFESSORS. LINE 7a: THE MEMBERS OF THE CORPORATION ELECT THE TRUSTEES. LINE 7b: THE MEMBERS OF THE CORPORATION MAY ALTER, AMEND, OR REPEAL THE BY-LAWS BY VOTE. POLICIES FORM 990, PART VI, SECTION B, LINES 11B, 12C AND 15A/B LINE 11B: THE FORM 990 IS PREPARED BY THE INSTITUTE, INTERNALLY REVIEWED BY THE SR. DIRECTOR OF FINANCE AND THE CHIEF FINANCIAL OFFICER AND EXTERNALLY REVIEWED BY THE TAX DEPARTMENT OF A PUBLIC ACCOUNTING FIRM. A COPY OF THE PREPARED FORM 990 IS PROVIDED TO ALL BOARD MEMBERS AND THE AUDIT COMMITTEE FOR REVIEW AND DISCUSSION PRIOR TO ELECTRONIC FILING. LINE 12C: ANNUALLY, THE CONFLICT OF INTEREST DISCLOSURE STATEMENT IS SENT OUT FOR COMPLETION BY THE MEMBERS OF THE BOARD OF TRUSTEES, SENIOR MEMBERS OF ADMINISTRATION AND RESEARCHERS. THE DESIGNATED OFFICIAL FOR EACH GROUP REVIEWS THE COMPLETED FORMS AND BRINGS ANY POTENTIAL CONFLICT OF INTEREST TO THE RESPECTIVE COMMITTEES FOR REVIEW. UPON DETERMINATION THAT A CONFLICT OF INTEREST EXISTS, THE FOLLOWING CONDITIONS OR RESTRICTIONS MAY BE IMPOSED: A. MONITORING OF ACTIVITIES GENERATING THE CONFLICT BY ANOTHER MEMBER; B. DISQUALIFICATION FROM PARTICIPATION IN THE ACTIVITIES GIVING RISE TO THE CONFLICT; C. MODIFICATION OF RESPONSIBILITIES TO AVOID CONFLICTS; D. PUBLIC DISCLOSURE OR DIVESTITURE OF SIGNIFICANT FINANCIAL INTERESTS; E. MODIFICATION OF THE RESEARCH PLAN OR REMOVAL OF THE AFFECTED RESEARCHER FROM THE RESEARCH; F. SEVERANCE OF RELATIONSHIP THAT CREATES ACTUAL OR POTENTIAL CONFLICTS; G. TERMINATION OF EMPLOYMENT. LINE 15A/B:AN INDEPENDENT CONSULTANT WAS RETAINED BY THE SALK INSTITUTE TO ADVISE ON COMPENSATION ISSUES. MARKET ANALYSIS ON THE COMPETITIVENESS OF THE BASE SALARY AND TOTAL COMPENSATION (INCLUDING BENEFITS) FOR THE CEO, EVP, AND CFO WERE CONDUCTED IN 2010. THE INDEPENDENT CONSULTANT EVALUATED TOTAL COMPENSATION COMPARED TO LIKE ROLES AMOUNT ORGANIZATIONS PROVIDING SUBSTANTIALLY SIMILAR SERVICES IN THE RESEARCH INDUSTRY, INCLUDING BOTH FOR-PROFIT AND NOT-FOR-PROFIT ORGANIZATIONS. THE CONSULTANT CONSIDERED THE SIZE AND SCOPE OF OPERATIONS OF THE INCUMBENTS. THE CONSULTANT GAVE THE OPINION THAT THE TOTAL COMPENSATION FALLS WELL WITHIN REASONABLE RANGE OF COMPETITIVE PRACTICES. THE CONSULTANT'S REPORTS WERE REVIEWED BY THE EXECUTIVE COMMITTEE WHICH SERVED AS THE COMPENSATION COMMITTEE, EXCLUDING PERSONS WITH A CONFLICT OF INTEREST WITH RESPECT TO THE COMPENSATION ARRANGEMENT. DOCUMENTATION AND RECORDKEEPING WITH RESPECT TO THE DELIBERATIONS AND DECISIONS REGARDING THE COMPENSATION PACKAGE WERE INCLUDED IN THE MINUTES OF THE EXECUTIVE COMMITTEE MEETING. A COPY OF THE CONSULTANT'S REPORTS WAS ATTACHED TO THE MINUTES OF THE MEETING. IN 2011, FOR 2012 CALENDAR YEAR COMPENSATION ACTIONS, AN INDEPENDENT CONSULTANT PROVIDED AN UPDATE TO THE 2010 ANNUAL REVIEW AND PROVIDED RECOMMENDATIONS ON 2012 COMPENSATION ACTIONS, AS APPROPRIATE. THE CONSULTANT GAVE THE OPINION THAT THE SALK'S EXECUTIVE CASH COMPENSATION PROGRAM CONTINUES TO BE BALANCED IN DESIGN, ALIGNED WITH THE SALK'S MISSION AND VALUES, AND REASONABLE IN AMOUNT. THE CONSULTANT'S REPORTS WERE REVIEWED BY THE EXECUTIVE COMMITTEE OF THE BOARD OF TRUSTEES WHICH SERVED AS THE COMPENSATION COMMITTEE, EXCLUDING PERSONS WITH A CONFLICT OF INTEREST WITH RESPECT TO THE COMPENSATION ARRANGEMENT. DOCUMENTATION AND RECORDKEEPING WITH RESPECT TO THE DELIBERATIONS AND DECISIONS REGARDING THE COMPENSATION PACKAGE WERE INCLUDED IN THE MINUTES OF THE EXECUTIVE COMMITTEE MEETING. A COPY OF THE CONSULTANT'S REPORTS WAS ATTACHED TO THE MINUTES OF THE MEETING. DISCLOSURE FORM 990, PART VI, SECTION C, LINE 19 UPON REQUEST, THE OFFICE OF THE CHIEF FINANCIAL OFFICER MAKES AVAILABLE TO THE PUBLIC ITS GOVERNING DOCUMENTS AND CONFLICT OF INTEREST POLICY. FINANCIAL STATEMENTS ARE AVAILABLE ON THE SALK WEB SITE. OTHER CHANGES IN NET ASSETS FORM 990, PART XI, LINE 5 UNREALIZED INVESTMENT LOSSES IN EXCESS OF AMOUNT DESIGNATED FOR CURRENT OPERATIONS - ($8,223,913); POSTRETIREMENT BENEFIT CHANGES OTHER THAN NET PERIODIC BENEFIT COST - ($46,931); ROUNDING - $2 COMPENSATION OF DIRECTORS PART VII, DIRECTORS COMPENSATION THE FOLLOWING INDIVIDUALS WERE COMPENSATED FOR THE FOLLOWING SERVICES AND NOT PAID AS TRUSTEES: GEOFFREY M. WAHL, PH.D. - PROFESSOR THOMAS D. ALBRIGHT, PH.D. - PROFESSOR CHRISTOPHER R. KINTNER, PH.D. - PROFESSOR LA JOLLA BIOLOGICAL LABORATORIES PO BOX 85800 - FINANCE SAN DIEGO CA 92186 953655649 Research CA 501(C)(3) 11-I NA false SALK INSTITUTE COMMERCIAL SERVICES CORP PO BOX 85800 - FINANCE SAN DIEGO CA 921865800 232159172 MGMT SERVICES PA SALK INSTITUTE C 132 54566 1.00000 false false false false false false false false false false false false true true false true false false